Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Morgan Stanley (NY:MS)

189.71 -1.31 (-0.69%)
Official Closing Price Updated: 4:10 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Morgan Stanley

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Morgan Stanley Sees Wealth, AI Financing and Deal Rebound Powering Growth ↗
Morgan Stanley (NYSE:MS) Co-President Dan Simkowitz said the firm does not view 2026 as a peak-earnings year, citing growth opportunities in wealth management, a developing capital-markets recovery and... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Honeywell Sees Strong Start as Pure-Play Automation Push Gains Momentum ↗
Honeywell International (NASDAQ:HON) Chairman and CEO Vimal Kapur said the company is seeing stronger-than-expected early-quarter momentum as it begins operating as a more focused automation business... 
Via MarketBeat
News headline image
Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities ↗
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas... 
Via MarketBeat
Topics ETFs
News headline image
Rivian Calls R2 Launch an Inflection Point as Demand, Autonomy Plans Accelerate ↗
Rivian Automotive (NASDAQ:RIVN) is entering what founder and CEO RJ Scaringe described as an “inflection point year,” as the electric-vehicle maker begins scaling its R2 midsize SUV and expands its... 
Via MarketBeat
Topics Supply Chain
News headline image
RTX Highlights $289B Backlog as Aerospace, Defense Demand Powers Growth ↗
RTX (NYSE:RTX) Chairman, President and CEO Chris Calio said the aerospace and defense company remains positioned to benefit from sustained commercial aviation and defense demand, citing a $289 billion... 
Via MarketBeat
News headline image
Medtronic Sees AI, Ablation and Targeted M&A Fueling Growth ↗
Medtronic (NYSE:MDT) Chief Financial Officer Thierry Piéton said the medical-device maker’s focus on acute procedures, expanding innovation pipeline and increased use of targeted acquisitions are... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
General Motors Sees Q3 on Track as Truck Launch, Digital Growth Fuel 2027 Outlook ↗
General Motors (NYSE:GM) Chief Financial Officer Paul Jacobson said the automaker’s business is tracking consistently with its expectations for the third quarter, supported by resilient consumer... 
Via MarketBeat
Topics Economy World Trade
News headline image
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances ↗
Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief... 
Via MarketBeat
Topics Intellectual Property
News headline image
AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline ↗
AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s... 
Via MarketBeat
Topics ETFs
News headline image
Stocks making big moves yesterday: Corning, Baldwin Insurance Group, Gartner, Jabil, and Accenture
Check out the companies making headlines yesterday: Corning (NYSE:GLW): Glass and electronic component manufacturer Corning (NYSE:GLW) fell by 12.7% on Monda... 
Via StockStory
Topics Artificial Intelligence
Wall Street Sells the AI-Pause Weekend as Brent Punches Through $106 and the Ten-Year Cracks 5% for the First Time Since 2023 ↗
Via Chartmill
News headline image
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗
Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic... 
Via MarketBeat
News headline image
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley... 
Via MarketBeat
News headline image
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗
Viking Therapeutics (NASDAQ:VKTX) said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13... 
Via MarketBeat
News headline image
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global... 
Via MarketBeat
Topics Intellectual Property
News headline image
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗
Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded... 
Via MarketBeat
Topics World Trade
News headline image
CRISPR Therapeutics Eyes CASGEVY Growth, Year-End Pipeline Catalysts ↗
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sam Kulkarni outlined the company’s commercial and clinical priorities during a Morgan Stanley discussion, highlighting continued adoption of CASGEVY and expected... 
Via MarketBeat
Topics Intellectual Property
News headline image
Merck CEO Sees Pipeline Upside as Launches, Animal Health Drive Transformation ↗
Merck & Co., Inc. (NYSE:MRK) Chairman and CEO Rob Davis said the company’s “transformation is underway,” citing progress across product launches, clinical data readouts, business development and its... 
Via MarketBeat
News headline image
Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗
Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing... 
Via MarketBeat
News headline image
Why Accenture (ACN) Stock Is Up Today
What Happened? Shares of global professional services company Accenture (NYSE:ACN) jumped 5.2% in the afternoon session after Morgan Stanley raised its price... 
Via StockStory
Topics Artificial Intelligence
News headline image
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition ↗
Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline... 
Via MarketBeat
Topics ETFs Economy
News headline image
Pfizer Says Major Headwinds Are Easing as Pipeline, Obesity Plans Take Center Stage ↗
Pfizer (NYSE:PFE) Chairman and Chief Executive Officer Albert Bourla said the drugmaker has addressed several major headwinds that weighed on investor attention, including policy uncertainty, declining... 
Via MarketBeat
Topics Intellectual Property World Trade
News headline image
Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types ↗
Moderna (NASDAQ:MRNA) President Stephen Hoge said the company’s recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma... 
Via MarketBeat
News headline image
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗
Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics... 
Via MarketBeat
News headline image
McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal ↗
McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology &... 
Via MarketBeat
News headline image
Morgan Stanley Inclusive & Sustainable Ventures Announces 2026 Global Cohort of Innovators
From Morgan Stanley
Via Business Wire
News headline image
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead ↗
Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company’s... 
Via MarketBeat
News headline image
Billionaire David Einhorn Says SpaceX Is Making History, but Not in a Good Way ↗
SpaceX will need substantial capital to pursue its various business ventures. 
Via The Motley Fool
Topics Bonds Initial Public Offering
News headline image
Joby Aviation Could Deliver 10x Returns for Patient Investors ↗
On paper, a tenfold gain isn't far-fetched, but can Joby deliver it? 
Via The Motley Fool
Topics Economy
News headline image
Here's How Much $100 Invested In Morgan Stanley 10 Years Ago Would Be Worth Today ↗
Morgan Stanley (NYSE:MS) has outperformed the market over the past 10 years by 7.4% on an annualized basis producing an average annual return of 20.97%. Currently, Morgan Stanley has a market... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.